Simplifying Global Compliance
MannKind Beset With Afrezza Clinical Trial Fraud Allegations
Washington Drug Letter
Less than two months before the FDA makes a decision on its inhaled insulin Afrezza, MannKind is facing allegations of clinical trial improprieties from a former employee.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing